Impact of Repeated Glucocorticoid Oral Administration on the Urinary Steroid Profile
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Sergi Coll und 6 weiteren Autor:innen. Beteiligte Einrichtung: Catalonian Antidoping Laboratory, Doping Control Research Group, Hospital del Mar Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Glucocorticoids, Methylprednisolone, Dexamethasone, Steroids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: AGAUR (Generalitat de Catalunya), World Anti-Doping Agency, Consell Català de l'Esport (Generalitat de Catalunya).
Abstract (Originalsprache)
The detection of endogenous anabolic androgenic steroids (EAAS) is performed with the Steroidal Module of the Athlete Biological Passport (ABP). Glucocorticoids (GC) could be a confounding factor to the ABP Steroidal Module because they inhibit the hypothalamic–pituitary–adrenal axis, and ABP metabolites have partial adrenal origin. In previous studies, single‐dose systemic GC administrations have been shown to reduce the urinary ratios A/T and 5αdiol/E. In this work, the impact of repeated oral doses of GCs on the urinary steroid profile (SP) has been evaluated. The treatments administered consisted of multiple oral administrations of methylprednisolone (12 mg/24 h for 3 days, n = 8) and dexamethasone (2 mg/12 h for 5 days, n = 8). Urine samples were collected before, during, and after the GC treatments, and the SP was measured in all samples using gas chromatography–tandem mass spectrometry. The multiple‐dose oral administration of GCs resulted in a treatment‐dependent reduction of the excretion rates of some urinary metabolites (5αAdiol, A, and Etio) and the urinary SP ratios A/T and 5αAdiol/E. The T/E ratio was not significantly affected. Overall, although the consumption of GC could result in atypical profiles for A/T and 5αAdiol/E ratios, according to the cost/benefit assessment, GC should not be considered a confounding factor to the urinary SP because misunderstandings would only take place in very specific situations and, in those cases, the analysis by isotope ratio mass spectrometry of the urine triggering the atypical profile would demonstrate the endogenous origin of the SP metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Catalonian Antidoping Laboratory, Doping Control Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
- Clinical Research Unit, Hospital del Mar Medical Research Institute, Barcelona, Spain.
- Integrative Pharmacology and Systems Neuroscience Group FINS, Hospital del Mar Research Institute, Barcelona, Spain.
ORCID-Profile: Sergi Coll, Claudia Bressan, Rosalia Ramírez, Núria Monfort, Rosa Ventura
Förderung
- AGAUR (Generalitat de Catalunya)
- World Anti-Doping Agency
- Consell Català de l'Esport (Generalitat de Catalunya)
- Agència de Gestió d'Ajuts Universitaris i de Recerca
Zitieren
APA
Coll, S., Hernández, D., Bressan, C., Ramírez, R., Monfort, N., Aldea-Perona, A., & Ventura, R. (2025). Impact of Repeated Glucocorticoid Oral Administration on the Urinary Steroid Profile. Drug Testing and Analysis. https://doi.org/10.1002/dta.3853
Vancouver
Coll S, Hernández D, Bressan C, Ramírez R, Monfort N, Aldea-Perona A, et al. Impact of Repeated Glucocorticoid Oral Administration on the Urinary Steroid Profile. Drug Testing and Analysis. 2025. doi:10.1002/dta.3853
BibTeX
@article{Coll2025,
author = {Coll, Sergi and Hernández, Deamelys and Bressan, Claudia and Ramírez, Rosalia and Monfort, Núria and Aldea-Perona, Ana and Ventura, Rosa},
title = {Impact of Repeated Glucocorticoid Oral Administration on the Urinary Steroid Profile},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3853}
}
EUVIMED